AHL Partners LLP lessened its position in Natus Medical Incorporated (NASDAQ:BABY) by 51.6% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 81,120 shares of the medical equipment provider’s stock after selling 86,384 shares during the period. AHL Partners LLP owned approximately 0.25% of Natus Medical worth $3,025,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of BABY. BlackRock Inc. raised its stake in shares of Natus Medical by 137,510.8% in the 1st quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock worth $161,874,000 after buying an additional 4,121,198 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Natus Medical by 105.7% in the 1st quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock worth $70,457,000 after buying an additional 922,268 shares in the last quarter. Epoch Investment Partners Inc. raised its stake in shares of Natus Medical by 68.3% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,110,932 shares of the medical equipment provider’s stock worth $43,604,000 after buying an additional 450,698 shares in the last quarter. Confluence Investment Management LLC raised its stake in shares of Natus Medical by 374.5% in the 2nd quarter. Confluence Investment Management LLC now owns 459,073 shares of the medical equipment provider’s stock worth $17,124,000 after buying an additional 362,326 shares in the last quarter. Finally, Lyon Street Capital LLC raised its stake in shares of Natus Medical by 65.6% in the 1st quarter. Lyon Street Capital LLC now owns 755,167 shares of the medical equipment provider’s stock worth $29,640,000 after buying an additional 299,151 shares in the last quarter. 92.66% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “AHL Partners LLP Reduces Stake in Natus Medical Incorporated (BABY)” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://stocknewstimes.com/2017/10/11/ahl-partners-llp-reduces-stake-in-natus-medical-incorporated-baby.html.
BABY has been the topic of a number of research reports. BidaskClub raised Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Zacks Investment Research cut Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $48.00.
In other news, Director William M. Moore sold 3,000 shares of the stock in a transaction on Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the transaction, the director now owns 30,410 shares of the company’s stock, valued at approximately $1,036,981. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert A. Gunst sold 4,400 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $35.17, for a total value of $154,748.00. Following the sale, the director now directly owns 50,850 shares in the company, valued at approximately $1,788,394.50. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.
Natus Medical Incorporated (BABY) opened at 40.15 on Wednesday. Natus Medical Incorporated has a one year low of $31.65 and a one year high of $43.85. The firm has a market capitalization of $1.31 billion, a PE ratio of 69.58 and a beta of 0.95. The company has a 50 day moving average price of $35.53 and a 200-day moving average price of $36.02.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.01. The company had revenue of $122.20 million for the quarter, compared to the consensus estimate of $121.99 million. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The firm’s quarterly revenue was up 27.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.39 EPS. On average, equities analysts predict that Natus Medical Incorporated will post $1.70 EPS for the current year.
Natus Medical Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.